Skip to Content
Merck
CN
  • Progressive familial intrahepatic cholestasis and inborn errors of bile acid synthesis.

Progressive familial intrahepatic cholestasis and inborn errors of bile acid synthesis.

Clinics and research in hepatology and gastroenterology (2012-05-23)
Irena Jankowska, Piotr Socha
ABSTRACT

Progressive familial intrahepatic cholestasis (PFIC), types 1, 2 and 3, are due to defects in genes involved in bile secretion (FIC1, BSEP, MDR3). PFIC and inborn errors of bile acid synthesis (IEBAS) often present in infancy with cholestasis. The distinctive feature of PFIC 1 and 2 and IEBAS is a normal level of GGT, while IEBAS are suspected in patients with low plasma bile acids concentration. Molecular testing, urinary bile acid analysis (IEBAS), liver biopsy and immuno-staining are used for the diagnosis. Some patients with PFIC can be successfully treated with ursodeoxycholic acid or partial external biliary diversion. IEBAS is treated with cholic acid. Liver transplantation is required for cirrhosis with liver failure. Hepatocarcinoma has been reported in PFIC2.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cholic acid, from bovine and/or ovine, ≥98%
Cholic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Cholic acid, Vetec, reagent grade, 98%